Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 12:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 179 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Terminated Phase 3 Interventional Results available

Hypertension in Hemodialysis Patients (Aim 3)

NCT00582114
Conditions
Hemodialysis, Hypertension, Left Ventricular Hypertrophy
Interventions
Lisinopril, Atenolol
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Completed No phase listed Observational Accepts healthy volunteers

Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS)

NCT03310684
Conditions
Pediatric Disorder, Pediatric Obesity, Primary Hypertension
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
5 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Hypertensive Disorder
Interventions
Blood pressure cuff
Device
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 54 Years · Female only
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Columbia, South Carolina
Conditions
Hypertension
Interventions
Metoprolol, Chlorthalidone
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Gainesville, Florida • Atlanta, Georgia • Rochester, Minnesota
Completed Phase 1Phase 2 Interventional Results available

Safety Study of RMJH-111b to Treat Essential Hypertension

NCT02822222
Conditions
Essential Hypertension
Interventions
Magnesium citrate, tribasic anhydrous soft gelatin capsule, Placebo soft gelatin capsule
Drug
Lead sponsor
RMJ Holdings, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Tustin, California
Conditions
Blood Pressure, Medication Adherence
Interventions
Electronic Health Record (EHR) Enabled Teamlets
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
1,842 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Hypertension, Hypertension, Systolic, Hypertension, Essential
Interventions
Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated, Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated
Device
Lead sponsor
Orchestra BioMed, Inc
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
72
States / cities
Scottsdale, Arizona • Glendale, California • Newport Beach, California + 60 more
Conditions
Pre-Eclampsia, Hypertension in Pregnancy, Pregnancy Complications, Hypertension, Pregnancy-Induced
Interventions
Furosemide, Placebo
Drug · Other
Lead sponsor
Melanie Maykin, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Honolulu, Hawaii
Conditions
Hypertension
Interventions
iPSC
Genetic
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients

NCT00952081
Conditions
Hypertension, Brain Tumor, Epilepsy
Interventions
Clevidipine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Completed Phase 4 Interventional Results available

Angiotensin II in General Anesthesia

NCT03733145
Conditions
Hypertension
Interventions
Angiotensin II
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Hypertension, Hemorrhage
Interventions
clevidipine
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Washington D.C., District of Columbia • Honolulu, Hawaii • Baltimore, Maryland + 11 more
Conditions
High Blood Pressure
Interventions
Control Condition, Regret Lottery
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Essential Hypertension, Older Adults
Interventions
chlorthalidone, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
60 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Chronic Hypertension Complicating Pregnancy (Diagnosis), Preeclampsia
Interventions
Labetalol Hydrocholoride 200 mg orally every 12 hours, Nifedipine 60 mg orally daily, Atenolol 25 mg daily
Drug
Lead sponsor
University of Tennessee Medical Center
Other
Eligibility
18 Years to 51 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Knoxville, Tennessee
Completed Not applicable Interventional

Home Blood Pressure Monitoring Project

NCT01162759
Conditions
Hypertension
Interventions
Home Blood Pressure Monitoring
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 85 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Denver, Colorado
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period

NCT04236258
Conditions
Hypertension in Pregnancy, Preeclampsia Severe, Gestational Hypertension, Postpartum Preeclampsia, Postpartum
Interventions
NIFEdipine ER, Enalapril
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Results available

Targeting of UnControlled Hypertension in Emergency Department

NCT03749499
Conditions
Hypertension, Cardiovascular Diseases, Vascular Diseases
Interventions
HTN Educational Video, Visual Echocardiogram Image Clips, Mobile Health and Remote BP monitoring, Post-Acute Care HTN Transition consultation (PACHT-c)
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Hypertension
Interventions
Nebivolol
Drug
Lead sponsor
Mercy Research
Other
Eligibility
18 Years to 90 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Completed Not applicable Interventional Accepts healthy volunteers Results available

Systolic Blood Pressure Intervention Trial

NCT01206062
Conditions
Hypertension
Interventions
Intensive control of SBP, Standard control of SBP
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
50 Years and older
Enrollment
9,361 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Recruiting Not applicable Interventional

Arterial Stiffness and Blood Pressure

NCT06495710
Conditions
Hypertension, Vascular Stiffness, Aging
Interventions
Blood pressure treatment algorithm
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Birmingham, Alabama • Nashville, Tennessee • Madison, Wisconsin
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Conditions
Hypertension
Interventions
Hydrochlorothiazide, Atenolol
Drug
Lead sponsor
University of Florida
Other
Eligibility
17 Years to 65 Years
Enrollment
1,701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
3
States / cities
Gainesville, Florida • Atlanta, Georgia • Rochester, Minnesota
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Preventing Sickle Cell Kidney Disease

NCT02373241
Conditions
Anemia, Sickle Cell, Sickle Cell Disease, Kidney Disease, Hypertension, Proteinuria
Interventions
Losartan
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
5 Years to 25 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama